We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oxford Pharm Gp | LSE:OXP | London | Ordinary Share | GB00B3LXPB43 | ORD 0.001P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.50 | 1.45 | 1.55 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
20/1/2014 16:24 | timbo, since you seem to be so convinced OXP is a pile of poo, what would you recommend I buy as a long-term investment instead? | doodlebug4 | |
20/1/2014 14:29 | Just been reading PCGH's annual report. They speak highly of OXP they also explain the investment themes driving growth across the sector. I don't have any OXP yet but I do have a PCGH holding (trading at a discount to NAV). Timbo003, thanks for your words of warning. Thankfully we live in a country with free speach and you are a strong enough character to ignore the tribal mentality evoked by the saftey of an internet BB. If it's not too much trouble would you be prepared to disclose what stocks you hold in the sector? | praipus | |
20/1/2014 13:15 | I appreciate bear case views on shares I hold until the bear case poster seems to become obsessed with expressing negative opinions. The minute someone posts a positive RNS, or a positive news item, or a postive opinion on OXP timbo immediately posts something negative. | doodlebug4 | |
20/1/2014 12:59 | I hold, and I greatly appreciate any negative views, particularly ones so well expressed as timbo's. I can never understand why holders are so often angered by people putting the bear case. I like to understand the bear case so I can properly assess the risk I run. | gnnmartin | |
20/1/2014 12:09 | timbo003 - why don't you get a life, your incessant obsession with knocking this share became extremely boring ages ago. We get the message - line and verse, line and verse - ad nauseaum. | doodlebug4 | |
17/1/2014 17:48 | I've been watching this thread for a while and personally I decided to sell most of my stake at a small profit.Ill trade on positive sentiment and leave the profits as free shares just in case. Looking at other pharma shares volitility is quite sobering. | rolandormrod | |
17/1/2014 16:03 | Yes Doodle, I was responding to Timmy but think you posted just at the same time. Anyway good weekend all, I am off to drink some wine | burbelly | |
17/1/2014 16:00 | Burberry, you misunderstood my post - it's not you I'm puzzled about! I was saying that I agreed with you about timbo's incessant knocking. :-) I also buy shares to make money. timbo, I would think that it's only the impatient, not the obstinate who have sold this share. "Hold for the long term and you will almost certainly lose money" - that is quite a prediction which may come back to haunt you ! | doodlebug4 | |
17/1/2014 15:45 | DB, yes I seem to be preaching to the unconvertable, although I suspect several of the wary have already left, just leaving the obstinate. The problem most investors have (myself included), is we tend to have a bullish bias and we put more emphasis on the bull case, rather than the bear case. Burbelly, yes, I'm sure it will be possible to make money trading this, but hold for the long term and you will almost certainly lose money. BTW, I turned up on this thread towards end of Feb 2013, with the share price at around 4p, so I don't think any of my pearls of wisdom, will have caused any investors to lose out on any meteoric rises. Hits since October 24th 2013 | timbo003 | |
17/1/2014 15:25 | Well dont be puzzled any longer, I trade to make money | burbelly | |
17/1/2014 15:23 | timbo003 - you are flogging a dead horse on this thread. Time will tell if you have got it right or wrong, but in the meantime the share price gradually keeps going up. Like Burbelly I find your relentless knocking rather puzzling and I suspect you have a hidden agenda - whatever it may be. | doodlebug4 | |
17/1/2014 15:15 | Burbelly, what I find puzzling is that you and others ignore an industry professional, who has made no secret of his background, who has worked and published extensively in this area and bought innovative products to the market, who probably knows far more than any analyst who has scribbled about the subject, who knows far more than any fund manager about the subject and almost certainly knows quite a bit more about developing ibuprofen dosage forms, than the R&D director at OXP. Hits since October 24th 2013 | timbo003 | |
17/1/2014 15:07 | Yes but the trouble is any PI who has been listening to you so far would be well out of pocket. What I find a puzzle is your relentless knocking, why dont you give it a rest and come back in q4 with some pie? | burbelly | |
17/1/2014 15:05 | Burbelly, I agree its tradeable and it may well go up in the short term, but I wouldn't want any ADVFN PIs to be too long on this when the brown stuff does hit the fan (probably in Q4). Hits since October 24th 2013 | timbo003 | |
17/1/2014 15:02 | Tim This has been a great share for me and I think there is plenty of millage in it yet, not even a hint of any bad news apart from your doom. Everyone else seem happy to pump serious cash into it, no one is selling And its tradeable as well as long as you have a little patience | burbelly | |
17/1/2014 14:59 | Q&A: Oxford Pharmascience expects strong sales to continue By Jeremy Naylor January 17 2014, 9:28am "We've got new markets opening up for that product and hopefully licensing deals coming through this year as well, so every reason why we should continue." In a transformational year, drug reformulation specialist Oxford Pharmascience (LON:OXP) saw a 122% rise in revenues over the period. Chief executive Nigel Theobald explains why he believes this trend will continue in 2014. Proactive Investors: Explain a little bit more about what's been happening and how this rise been achieved? Nigel Theobald: We're delighted that we've doubled sales again. We've been consistently growing our base business. The sales that we've achieved are primarily from our original calcium products that we sell in Asia and Brazil. The Brazilian partner, Aché, have just done exceptionally well with the product and that's been a major contributor to the sales group. It shows that when we do get products on market we will achieve very strong sales. That's really what our business is all about. PI: Can you envisage this sort of sales increase continuing this year? NT: I think so, yes. The growth rate is strong and we now have two products in Brazil. We have plans for further products with our partner Aché in Brazil. We've got new markets opening up for that product and hopefully licensing deals coming through this year as well, so every reason why we should continue. PI: Looking back to 2013, you had two fundraisings. You've got cash on the balance sheet from that just under £10 million at the moment. How long is this going to last? What is it going to enable you to do this year? NT: We raised the money to allow us to refocus our strategy on getting products to dossier. In this market it's very important that you can have dossiers for the product, because a dossier gives you the ability to then make an application to a country to get the marketing approval for that product to then be sold. We've raised enough money now to get two to three products right the way through to dossier, focusing on the NSAIDs [non-steroidal anti-inflammatory drugs] programme. We'll have one GI-safe [gastrointestinal-sa PI: What's the message then for investors this year and those looking at this thinking, "this is a good opportunity"? NT: Well last year, 2013, really was all about us building up our capability in the clinical area so that we could get products through to dossier rather than just licensing technology for pharma companies to do it themselves. The funding that we've got allows us to get the product through to that dossier and then we licence the dossier. It's a slight change in the commercial strategy but it puts us in a much stronger position. 2014 then is really going to be about increasing our capability to do the commercial deals. Now having got the clinical programme very firmly established and underway, 2014 is about getting out and talking to the pharma partners and bringing in those commercial deals next year and beyond. . | doodlebug4 | |
17/1/2014 14:59 | Lol. Tell me Burbelly, if you had to assign a probability of technical success (as a percentage) for the forthcoming OXP001 proof of concept study, what sort of value would you put on it. I would go for less than 1% | timbo003 | |
17/1/2014 14:50 | Ill buy it for you. | burbelly | |
17/1/2014 14:48 | Yep and the lets order in the humble pie for Q4, because one of us is going to be eating it. | timbo003 | |
17/1/2014 14:45 | yep and lets watch the price | burbelly | |
17/1/2014 14:39 | 6 million buy? More accurate to say 6M trade. For every buyer, needless to say, there has to be a seller. | timbo003 | |
17/1/2014 14:23 | Throwing money at the white elephant! | burbelly | |
17/1/2014 13:36 | 6million buy @ 4.05p gone through. | doodlebug4 |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions